Novo Nordisk shares tumble after drug trial falls short Markets Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff. The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 257.23 Danish Krone on Monday morning after trials of its new obesity shot, [...]
Exclusive: NHS must keep medicine clawback down or lose investment, says weight-jab boss Retail The NHS must keep its medicines clawback tax low and predictable or else risk disrupting the rollout of weight-loss drugs in the UK, Novo Nordisk’s UK chief has said. Sebnem Avsar Tuna, general manager of UK operations for the Ozempic and Wegovy maker, told City PM the Government must keep in place the current ceiling [...]
Aviva Investors warns three funds failing on performance Investing Aviva Investors has flagged three of its funds as failing to deliver value for customers on performance, though it said no changes will be made to the funds. Aviva, which manages 15 investment funds, revealed in its latest Assessment of Value report that three funds are struggling to beat their benchmark. Asset managers are required [...]
Ozempic and Wegovy: What happens when a drug goes viral? May 18, 2024 Novo Nordisk's Wegovy and Ozempic have been heralded as the solution to the world's growing obesity problems. But when celebrities and influencers misuse them and start documenting their weight loss journeys online, should we take stock?
The Notebook: Where are retail investors putting their money? May 8, 2024 | City Talk Victoria Scholar takes the Notebook pen to talk retail investors, Ozempic's fat profits, and the UK's inflation forecast.
Are LVMH, Nestle, L’Oreal and Hermes Europe’s alternative to Microsoft, Apple, Nvidia and Tesla? April 9, 2024 Much has been made of the 'Magnificent Seven' tech stocks - Meta, Apple, Amazon. Alphabet, Microsoft, Nvidia and Tesla - which have dominated the US market amid a boom in demand for AI and, until recently, more optimism over potential interest rate cuts.
